432 filings
Page 3 of 22
6-K
ddm1p3quyuk9t8rbwun
15 Jul 20
Primary Document
5:29pm
6-K
aidu5d0m188tro1hanze
2 Jul 20
Primary Document
11:09am
6-K
eqwxj eoqfbqu8522
29 May 20
Primary Document
5:28pm
6-K
zqq301vyn1f7sgyr
10 Apr 20
Intellipharmaceutics Provides Timing of First Quarter 2020 Results
12:00am
6-K
lkvdn5 t31iz1240yi
28 Feb 20
Primary Document
4:42pm
6-K
kx40 pu9noy6a
28 Feb 20
Primary Document
4:40pm
6-K
87rqvvipy xckyaibmla
5 Feb 20
Intellipharmaceutics Announces Resignation of Chief Financial Officer
5:04pm
6-K
s3f m0l5oeblc
16 Jan 20
Primary Document
8:09am
424B3
pti0x2y751j3jdxnlk
7 Jan 20
Prospectus supplement
2:33pm
424B3
r1y 48lmmzy02or9kuw
7 Jan 20
Prospectus supplement
2:30pm
6-K
jhwvq
5 Dec 19
Primary Document
9:36am
6-K
m7k fctfp6ttrgxco
25 Nov 19
Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Tris Pharma, Inc. for Venlafaxine ER
4:39pm
6-K
z60fz q1mzb6g2t18jd
18 Nov 19
Intellipharmaceutics Closes USD$250,000 Convertible Debenture Financing
4:38pm
6-K
iliolnk 2ec5
7 Nov 19
Intellipharmaceutics Announces Settlement Agreement in Class Action Lawsuit, Which is Subject to Court Approval
4:20pm
6-K
h04bgf2sjm3imn
24 Oct 19
Intellipharmaceutics Update on its Oxycodone ER New Drug Application
1:48pm
6-K
hftmn a628wd7e
11 Oct 19
Primary Document
5:20pm
6-K
g0rdi95jewq12
4 Oct 19
Intellipharmaceutics Announces an Update in the Purdue Litigation
8:07am
6-K
67usk ye736fgokns5e
5 Sep 19
Primary Document
1:44pm
6-K
s8e40
15 Aug 19
Primary Document
3:28pm